Supporting Seamless Execution Across Early Phase Alzheimer's Trials

Advancing a novel Alzheimer's treatment through three consecutive early-phase studies across 18 sites is a complex undertaking under any circumstances. During the COVID-19 pandemic, the program faced compounding obstacles, including participant hesitancy to enroll, inefficiencies introduced by intermediary consultant layers, high turnover among vendor support staff, and compressed timelines for single- and multiple-ascending-dose studies. This study reviews how the program overcame these hurdles by streamlining oversight and maintaining near-daily sponsor communication, completing the entire early-phase program on time and on budget.

If your team is managing multi-phase Alzheimer's research with tight timelines and shifting site conditions, this case study demonstrates how the right operational approach keeps a program on track from first dose to long-term safety evaluation.